<article id="tolerability_BRVO" class="slide" data-ag-name="Tolerability BRVO">
  <div class="tab-title">BRVO</div>
  <h2 class="slide-title">DEMONSTRATED TOLERABILITY<sup class="footnote-link">1</sup></h2>
   <p>Of the 1115 intravitreal injections during the Phase III trial, one serious AR related to the injection procedure (traumatic&nbsp;cataract) occurred.</p>
  <div class="chart-header">Most common ARs reported in â‰¥5% of patients treated with EYLEA<sup class="reg">&reg;</sup> through Week 52</div>
  <div class="chart-img"><img src="content_EN/img/charts_t-brvo.png" /></div>
</article>